Comment on “Novel cholesterol lowering drugs: Can phase 2/3 clinical trial safety assessments predict cardiovascular event outcome trial efficacy?”
- DOI
- 10.1016/j.ahjo.2026.100952
- Published
- 2026-11
- Container
- American Heart Journal Plus: Cardiology Research and Practice
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.ahjo.2026.100952,
title = {Comment on “Novel cholesterol lowering drugs: Can phase 2/3 clinical trial safety assessments predict cardiovascular event outcome trial efficacy?”},
author = {P.S. Raghu and Ramica Sharma and Manish R. Bhise},
year = {2026},
journal = {American Heart Journal Plus: Cardiology Research and Practice},
doi = {10.1016/j.ahjo.2026.100952},
url = {https://doi.org/10.1016/j.ahjo.2026.100952}
}RIS
TY - JOUR TI - Comment on “Novel cholesterol lowering drugs: Can phase 2/3 clinical trial safety assessments predict cardiovascular event outcome trial efficacy?” AU - P.S. Raghu AU - Ramica Sharma AU - Manish R. Bhise PY - 2026 JO - American Heart Journal Plus: Cardiology Research and Practice DO - 10.1016/j.ahjo.2026.100952 UR - https://doi.org/10.1016/j.ahjo.2026.100952 ER -
APA
Raghu, P., Sharma, R., & Bhise, M. R. (2026). Comment on “Novel cholesterol lowering drugs: Can phase 2/3 clinical trial safety assessments predict cardiovascular event outcome trial efficacy?”. American Heart Journal Plus: Cardiology Research and Practice. https://doi.org/10.1016/j.ahjo.2026.100952
Source records
- crossref · retrieved 2026-11-10T12:40:13.651Z